收稿日期: 2024-01-02
网络出版日期: 2024-07-15
基金资助
广东省自然科学基金项目(2017A030313559)
Aiming for the future： The latest advances in targeted therapy for ovarian cancer
Received date: 2024-01-02
Online published: 2024-07-15
黄山高 , 吴月玲 , 张颖 . 瞄准未来：卵巢癌靶向治疗的新进展[J]. 实用医学杂志, 2024 , 40(14) : 1901 -1907 . DOI: 10.3969/j.issn.1006-5725.2024.14.001
Ovarian cancer represents a significant threat to women's health globally， with particularly high recurrence and mortality rates in China's context of gynecological malignancies. The effectiveness of traditional therapeutic approaches for advanced and recurrent ovarian cancer remains quite limited. However， recent studies have highlighted the substantial success of targeted therapies in managing ovarian cancer. This paper delves into both national and international research on ovarian cancer's targeted treatments， examining their mechanisms， applications， current landscape， and the challenges they face. It aims to offer innovative perspectives and directions for ovarian cancer treatment.
Key words： ovarian cancer; targeted rherapy; PARP Inhibitors; ADCs; research progress
| 1 | LHOTOVA K， STOLAROVA L， ZEMANKOVA P， et al. Multigene Panel Germline Testing of 1333 Czech Patients with Ovarian Cancer ［J］. Cancers （Basel）， 2020，12（4）：956. doi:10.3390/cancers12040956 |
| 2 | WANG Y， WANG Z， ZHANG Z， et al. Burden of ovarian cancer in China from 1990 to 2030： A systematic analysis and comparison with the global level ［J］.Front Public Health， 2023，11：1136596. doi:10.3389/fpubh.2023.1136596 |
| 3 | BEREK J S， RENZ M， KEHOE S， et al. Cancer of the ovary， fallopian tube， and peritoneum： 2021 update ［J］.Int J Gynaecol Obstet， 2021，155（Suppl 1）：61-85. doi:10.1002/ijgo.13878 |
| 4 | LI S， TOPATANA W， JUENGPANICH S， et al. Development of synthetic lethality in cancer： molecular and cellular classification ［J］. Signal Transduct Target Ther， 2020，5（1）：241. doi:10.1038/s41392-020-00358-6 |
| 5 | BANERJEE S， MOORE K N， COLOMBO N， et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation （SOLO1/GOG 3004）： 5-year follow-up of a randomised， double-blind， placebo-controlled， phase 3 trial ［J］. Lancet Oncol， 2021，22（12）：1721-1731. doi:10.1016/s1470-2045(21)00531-3 |
| 6 | LEE J， LEE Y， PARK J， et al. Major clinical research advances in gynecologic cancer in 2022： highlight on late-line PARP inhibitor withdrawal in ovarian cancer， the impact of ARIEL-4， and SOLO-3 ［J］. J Gynecol Oncol， 2023，34（2）：e51. doi:10.3802/jgo.2023.34.e51 |
| 7 | VENEZIANI A C， SCOTT C， WAKEFIELD M J， et al. Fighting resistance： post-PARP inhibitor treatment strategies in ovarian cancer ［J］. Ther Adv Med Oncol， 2023，15：2602380. doi:10.1177/17588359231157644 |
| 8 | MAIORANO M F P， MAIORANO B A， BIANCOFIORE A， et al. Niraparib and Advanced Ovarian Cancer： A Beacon in the Non-BRCA Mutated Setting ［J］. Pharmaceuticals （Basel）， 2023，16（9）：1261. doi:10.3390/ph16091261 |
| 9 | DISILVESTRO P， BANERJEE S， COLOMBO N， et al. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation： The SOLO1/GOG 3004 Trial ［J］. J Clin Oncol， 2023，41（3）：609-617. doi:10.1200/jco.22.01549 |
| 10 | AUGUSTIN H G， KOH G Y. Antiangiogenesis： Vessel Regression， Vessel Normalization， or Both？ ［J］. Cancer Res， 2022，82（1）：15-17. doi:10.1158/0008-5472.can-21-3515 |
| 11 | ARORA S， BALASUBRAMANIAM S， ZHANG H， et al. FDA Approval Summary： Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer ［J］. Oncologist， 2021，26（1）：e164-e172. doi:10.1002/onco.13551 |
| 12 | MARCHETTI C， MUZII L， ROMITO A， et al. First-line treatment of women with advanced ovarian cancer： focus on bevacizumab ［J］. Onco Targets Ther， 2019，12：1095-1103. doi:10.2147/ott.s155425 |
| 13 | BURGER R A， SILL M W， MONK B J， et al. Phase Ⅱ trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer： a Gynecologic Oncology Group Study ［J］. J Clin Oncol， 2007，25（33）：5165-5171. doi:10.1200/jco.2007.11.5345 |
| 14 | AGHAJANIAN C， BLANK S V， GOFF B A， et al. OCEANS： a randomized， double-blind， placebo-controlled phase Ⅲ trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian， primary peritoneal， or fallopian tube cancer［J］. J Clin Oncol， 2012，30（17）：2039-2045. doi:10.1200/jco.2012.42.0505 |
| 15 | HAUNSCHILD C E， TEWARI K S. Bevacizumab use in the frontline， maintenance and recurrent settings for ovarian cancer ［J］. Future Oncol， 2020，16（7）：225-246. doi:10.2217/fon-2019-0042 |
| 16 | HETTLE R， MCCREA C， LEE C K， et al. Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer ［J］. Ther Adv Med Oncol， 2021，13：17505625. doi:10.1177/17588359211049639 |
| 17 | MIRZA M R， ?VALL LUNDQVIST E， BIRRER M J， et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer （NSGO-AVANOVA2/ENGOT-ov24）： a randomised， phase 2， superiority trial ［J］. Lancet Oncol， 2019，20（10）：1409-1419. doi:10.1016/s1470-2045(19)30515-7 |
| 18 | MERIC-BERNSTAM F， MAKKER V， OAKNIN A， et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors： Primary Results From the DESTINY-PanTumor02 Phase Ⅱ Trial ［J］. J Clin Oncol， 2024，42（1）：47-58. doi:10.1200/jco.23.02005 |
| 19 | HEO Y. Mirvetuximab Soravtansine： First Approval ［J］. Drugs， 2023，83（3）：265-273. doi:10.1007/s40265-023-01834-3 |
| 20 | MOORE K N， OZA A M， COLOMBO N， et al. Phase Ⅲ， randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer： primary analysis of FORWARD I ［J］. Ann Oncol， 2021，32（6）：757-765. doi:10.1016/j.annonc.2021.02.017 |
| 21 | GILBERT L， OAKNIN A， MATULONIS U A， et al. Safety and efficacy of mirvetuximab soravtansine， a folate receptor alpha （FRalpha）-targeting antibody-drug conjugate （ADC）， in combination with bevacizumab in patients with platinum-resistant ovarian cancer ［J］. Gynecol Oncol， 2023，170：241-247. doi:10.1016/j.ygyno.2023.01.020 |
| 22 | MOORE K N， ANGELERGUES A， KONECNY G E， et al. Phase Ⅲ MIRASOL （GOG 3045/ENGOT-ov55） study： Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant， advanced high-grade epithelial ovarian， primary peritoneal， or fallopian tube cancers with high folate receptor-alpha expression ［J］. J Clin Oncol， 2023，41（）：LBA5507. doi:10.1200/jco.2023.41.17_suppl.lba5507 |
| 23 | MANZANO A， OCANA A. Antibody-Drug Conjugates： A Promising Novel Therapy for the Treatment of Ovarian Cancer ［J］. Cancers （Basel）， 2020，12（8）：2223. doi:10.3390/cancers12082223 |
| 24 | EMBABY A， KUTZERA J， GEENEN J J， et al. WEE1 inhibitor adavosertib in combination with carboplatin in advanced TP53 mutated ovarian cancer： A biomarker-enriched phase Ⅱ study ［J］. Gynecol Oncol， 2023，174：239-246. doi:10.1016/j.ygyno.2023.05.063 |
| 25 | ZHANG C， PENG K， LIU Q， et al. Adavosertib and beyond： Biomarkers， drug combination and toxicity of WEE1 inhibitors ［J］. Crit Rev Oncol Hematol， 2023，193：104233. doi:10.1016/j.critrevonc.2023.104233 |
| 26 | BARTOLETTI M， PELIZZARI G， GERRATANA L， et al. Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer： A Network Meta-Analysis ［J］. Int J Mol Sci， 2020，21（11）：3805. doi:10.3390/ijms21113805 |
| 27 | MAREI H E， CENCIARELLI C， HASAN A. Potential of antibody-drug conjugates （ADCs） for cancer therapy ［J］. Cancer Cell Int， 2022，22（1）：255. doi:10.1186/s12935-022-02679-8 |
| 28 | TONG J T W， HARRIS P W R， BRIMBLE M A， et al. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy ［J］. Molecules， 2021，26（19）：5847. doi:10.3390/molecules26195847 |
| 29 | 王涛， 宋飞雪. 铂耐药卵巢癌的免疫治疗进展［J］. 2021，37（20）：2575-2579. doi:10.3969/j.issn.1006-5725.2021.20.002 |
| 30 | 尹萍， 徐寒子， 朱晨静. 循环肿瘤DNA在妇科恶性肿瘤中的应用［J］.实用医学杂志， 2023，39（17）：2153-2158. doi:10.3969/j.issn.1006-5725.2023.17.001 |
| 31 | 彭佳欣， 张自辉， 洪莉. m6A修饰在卵巢癌中的研究进展［J］. 实用医学杂志， 2023，39（12）：1577-1583. doi:10.3969/j.issn.1006-5725.2023.12.020 |
/
| 〈 |
|
〉 |